https://www.selleckchem.com/pr....oducts/pexidartinib-
007 and P = 0.013, respectively), were significantly lower in patients with hematologic malignancy than in those with Sweet syndrome only. No significant difference in histopathology was found between patients with and without hematologic malignancy. Systemic corticosteroids were the most frequently used treatment (24/37, 65%). Higher mortality was found in patients with hematologic malignancy. Conclusion It is important to assess Sweet syndrome patients who have laboratory evidence of lower hemoglobin and platelet levels f
Like
Comment
Share
